Table 1.

Summary of approved or investigational therapeutic drug to lower Lp(a) and LDL-C.

Approved and Investigational Drugs to Lower Lp(a) and LDL-C
Mechanism	Agent	Lp(a) Δ%	LDL-C Δ%	STATUS	Specific for Lp(a)
Reduce production of new Lp(a)/LDL-C	Statins	↑ 0–20	↓ 19–60	Approved	no
	Niacin	↓ 30–40	↓ >45	Approved	no
	Fibrates	-	↓ 10–30	Approved	no
	EPA/DHA	-	-	Approved	no
	Probucol	-	↓ 11–33	Approved	no
	Mipomersen	↓ 20–33	↓ 21–40	Approved	no
	IONIS APO(a)Lrx	↓ 39–92	-	Investigational	yes
	Lomitapide	↓ 19–51	↓ 15–15	Approved	no
	CEPT inhibitors	↓ 14–26	-	Stopped	no
	Aspirin	↓ 10–80	-	Approved	no
Increase LDLR expression for Lp(a)/LDL uptake	Evolocumab	↓ 30	↓ 39–75	Approved	no
	Alirocumab	↓ 30	↓ 29–73	Approved	no
	Inclisiran	↓ 26	↓ >60	Investigational	no

↑ increasing value; ↓ decreasing value.